Achaogen, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 20 rows in 2016. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2016-11-18: Reporting owner LOEB GARY; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2016-11-18: Reporting owner LOEB GARY; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2016-09-23: Reporting owner Sarpangal Zeryn; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2016-07-05: Reporting owner Schilke Tobin; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2016-11-18 | LOEB GARY Officer (General Counsel) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +57,000 57,000 owned after | $4.86 exercise price | 2016-11-23 | |
| 2016-11-18 | LOEB GARY Officer (General Counsel) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +14,000 14,000 owned after | $4.86 exercise price | 2016-11-23 | |
| 2016-09-23 | Sarpangal Zeryn Officer (VP, HR and Corporate Affairs) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +18,000 18,000 owned after | $4.34 exercise price | 2016-09-27 | |
| 2016-07-05 | Schilke Tobin Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $4.09 exercise price | 2016-07-06 | |
| 2016-07-05 | Schilke Tobin Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +26,000 26,000 owned after | $4.09 exercise price | 2016-07-06 | |
| 2016-06-15 | ROBERTS BRYAN E Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $4.84 exercise price | 2016-06-17 | |
| 2016-06-15 | STEA GREGORY Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $4.84 exercise price | 2016-06-17 | |
| 2016-06-15 | Lieginger Kent Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $4.84 exercise price | 2016-06-17 | |
| 2016-06-15 | Colowick Alan Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $4.84 exercise price | 2016-06-17 | |
| 2016-06-15 | Smither John W Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $4.84 exercise price | 2016-06-17 | |
| 2016-06-15 | DOYLE JOHN C Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $4.84 exercise price | 2016-06-17 | |
| 2016-06-15 | Fischbach Michael Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $4.84 exercise price | 2016-06-17 | |
| 2016-02-26 | Hillan Kenneth J. Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +77,500 77,500 owned after | $3.65 exercise price | 2016-03-01 | |
| 2016-02-26 | Hillan Kenneth J. Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +38,750 38,750 owned after | $3.65 exercise price | 2016-03-01 | |
| 2016-02-26 | Hillan Kenneth J. Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +38,750 38,750 owned after | $3.65 exercise price | 2016-03-01 | |
| 2016-02-26 | Friedland Ian Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +44,000 44,000 owned after | $3.65 exercise price | 2016-03-01 | |
| 2016-02-26 | Friedland Ian Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $3.65 exercise price | 2016-03-01 | |
| 2016-02-26 | Wise Blake Officer (Chief Operating Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +38,750 38,750 owned after | $3.65 exercise price | 2016-03-01 | |
| 2016-02-26 | Sarpangal Zeryn Officer (VP, HR and Corporate Affairs) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +18,000 18,000 owned after | $3.65 exercise price | 2016-03-01 | |
| 2016-02-26 | Sarpangal Zeryn Officer (VP, HR and Corporate Affairs) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $3.65 exercise price | 2016-03-01 |